Table 1.
Comparison of guidelines of adjuvant chemotherapy for gastric cancer
| Guideline | Methods of adjuvant therapy | Regimen |
| NCCN | Postoperative chemoradiation (preferred) | 5-FU plus irradiation |
| Perioperative chemotherapy | ECF | |
| Modification of ECF | ||
| Postoperative chemotherapy (only after D2 lymph node dissection) | XELOX | |
| Capecitabine plus cisplatin | ||
| ESMO | Perioperative chemotherapy (preferred) | ECF |
| Modification of ECF | ||
| Postoperative chemotherapy (patients without preoperative therapy) | S-1 monotherapy | |
| XELOX | ||
| Postoperative chemoradiation (for undertreatment surgery) | 5-FU plus irradiation | |
| Japanese | Postoperative chemotherapy | S-1 monotherapy (preferred) |
| S-1 plus oxaliplatin | ||
| XELOX |
5-FU: 5-Fluorouracil; ECF: Epirubicin, cisplatin, and 5-fluorouracil; ESMO: European Society for Medical Oncology; NCCN: National Comprehensive Cancer Network; XELOX: Capecitabine plus oxaliplatin.